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Abstract 
The immune system has been recognized as one of the most important regulators of 
bone turnover and its de-regulation is implicated in several bone diseases as post-
menopausal osteoporosis and inflammatory bone loss; recently it has been suggested 
that the gut microbiota may influence bone turnover by the modulation of immune system.  
The study of the relationship between immune system and bone metabolism is generally 
indicated under the term “osteoimmunology”, the vast majority of these studies have been 
performed in animal models, however several data have been confirmed also in humans: 
this review summarizes recent data on the relationship between immune system and 
bone with particular regard to the data confirmed in humans. 
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Introduction 
Bone is an active tissue that undergoes continuous remodelling, the increase in bone 
resorption with unbalanced bone formation leads to bone diseases characterized by bone 
loss. Bone turnover is due to the combined action of bone resorbing cells, osteoclasts 
(OCs) and bone forming cells, osteoblasts (OBs). The regulation of these two cell types is 
due to multiple systemic and local factors as hormones, cytokines and mechanical load. 
The immune system has been recognized as one of the important regulators of bone 
turnover and its de-regulation is implicated in several bone diseases. 
The interaction between immune system and bone has been deeply studied in condition 
as inflammatory diseases and post-menopausal osteoporosis.1 Recently it has been 
suggested that gut microbiota may influence bone loss trough the modulation of immune 
system.2 Several data on the interaction between immune system and bone have been 
generated in animal models, whereas human data are scarce, the aim of this paper is to 
review the current knowledge on the role of immune system in the control of bone 
metabolism pointing out data confirmed in humans with particular regard to inflammatory 
diseases, post-menopausal osteoporosis and the role of gut microbiota. 
 
Inflammatory diseases, immune system and bone. 
Rheumatoid arthritis (RA) is the paradigmatic disease linking immune alteration and bone 
metabolism. RA is a chronic disease characterized by immune deregulation associated 
with articular bone erosions, regional and systemic bone loss. Bone loss in RA is 
multifactorial, however, at least during the early disease phases, it is due to the activation 
of T cells that produce pro-osteoclastogenic cytokines.  
The unbalance of T helper (Th) cells sub-types in RA may be the first driver of increased 
osteoclastogenesis in these patients. In RA different alterations of Th sub-set have been 
described, in humans conflicting results have been obtained, depending on different 
study designs, some studies analyse T cells in peripheral blood whereas others evaluate 
these cells in the synovial fluids.3 The increased Th1 cells may have an important role in 
the pathogenesis of RA, these cells are increased in the synovium.3 Th1 produces 
several cytokines that have been related to the control of bone turnover as IFNγ, TNFα 
and RANKL: IFNγ has controversial effect on OCs formation and activity, it was found 
both to inhibit and to activate OCs;1 more recently it has been suggested that IFNγ is 
responsible for the ability of OCs to act as antigen presenting cells and to modulate T‐cell 
proliferation.4  
TNFα and RANKL are well known pro-osteoclastogenic cytokines;5 TNF-α induces OCs 
formation in presence of adequate levels of RANKL,5 up-regulates stromal cells 
production of RANKL and increases the responsiveness of OCs precursors to RANKL. 
RANKL plays an essential role in bone physiology by up-regulating OCs activity and 
formation, its role is antagonized by its decoy receptor osteoprotegerin (OPG): the 
RANKL, OPG ratio is the main regulator of OCs formation and activity. In RA patients 
RANKL levels predict the therapeutic response to anti-TNF therapy,6 and denosumab, 
which is an anti-RANKL monoclonal antibody, blocks the effect of increased RANKL on 
bone loss in RA patients by reducing bone resorption.7  
Th17 are increased in RA, and play a crucial pathogenetic role in the appearance of bone 
erosions in mice,3,8 in humans Th17 are recruited within synovium, where they exert pro-
inflammatory and pro-osteoclastogenic effect.9 Th17 cells produce IL-17, this cytokine is 
increased in RA,10 and plays a crucial role in inflammation and in the development of the 
disease; however, its mechanism of action in the development of bone loss, especially in 
relation to other known key cytokines such as IL-1, TNF-α and RANKL remains unclear. 
Recently, IL-17 has been suggested to be involved in the up-regulation of OCs formation 
in inflammation by increasing the release of RANKL, which may synergise with IL-1 and 
TNF-α.11 
T regulatory cells (Tregs) are known as crucial in maintaining the peripheral tolerance 
mechanism and in preventing autoimmunity, hence a decreased number of Treg or a 
reduced function of these cells are possible factors involved in the chronic inflammation 
observed in RA joint. However different studies on Tregs phenotype and function in RA 
patients obtained conflicting results: some studies found a decrease in Tregs in peripheral 
blood from RA patients;12,13 whereas others do not.14,15  
In experimental models of arthritis Tregs have been shown to inhibit OCs formation and 
activity,16 these data have been confirmed by our group also in humans during 
periprosthetic osteolysis.17  
Non-conventional T cells as γδ T cells have been suggested to play a pathogenetic role in 
a murine model of RA trough the production of IL-1718 , however this role has not been 
confirmed in humans19,20. In RA patients an increased number of γδ T cells have been 
found in the synovia, however Th17 and not IL-17 positive γδ T cells seem to drive bone 
erosions in humans19. A cross-talk between γδ T cells and OCs has also been investigated 
in vitro, in particular it has been suggested that OCs are able to recruit and activate γδ T 
cells trough the production of TNFα21 , on the contrary activated γδ T cells inhibit OCs 
formation and activity trough IFNγ production in co-cultures22 . The conflicting results in 
animal models, humans and in vitro suggest that a clear role for γδ T cells in the control of 
bone remodeling is not cleary established yet.  
Taken together these data suggest that both an increase of Th1 and Th17 may be 
responsible for increased OCs formation and bone erosions in RA, whereas a role for 
Tregs and γδ T cells is more controversial.  
T cells interacts with OCs not only through the production of cytokines, but also trough a 
cell to cells interaction; OCs behave like antigen presenting cells (APCs), they share a 
common precursor with dendritic cells and macrophages. OCs express major 
histocompatibility complex (MHC) molecules23, and costimulatory molecules involved in 
the regulation of T cells answers to immune stimuli as CD80 and CD86. CD80 and CD86 
are expressed on professional APCs as well as on OCs and bind CD28 that is expressed 
on activated T cells, T cells activation is tightly regulated by molecules that interrupt 
CD80/86 and CD 28 signal as CTLA-4 that is expressed on activated T cell surface. Hence 
CTLA-4 modulates APCs function. These molecules play an essential role also in OCs-T 
cells interaction as it has been brilliantly demonstrated CD80/86-deficient mice display 
increased osteoclast differentiation as CD80/86-deficient OCs are not inhibited by CTLA-4 
or Tregs24 . In humans the use of abatacept that targets CD80/86 reduces OCs formation, 
whereas the use of ipilimumab that blocks CTLA-4 increases OCs formation. The 
interaction between T cells and OCs may be a fundamental mechanism of increased 
osteoclastogenesis in RA. 
Accordingly to a possible function of OCs as APCs, a role for auto antibodies in bone 
destruction in RA patients has been postulated. It has been demonstrated that OCs 
function is influenced by antibodies, Fc receptors, and related molecules. In particular, in 
RA patients a direct effect of anti–citrullinated protein antibody (ACPAs) in the control of 
osteoclasogenesis has been demonstrated; it is known that in more than 70% of patients 
with RA ACPAs are detectable. Positivity for ACPAs is a strong predictor of bone erosions 
in RA, and ACPAs bind to OCs and stimulate osteoclast-mediated bone resorption by 
increasing the production of TNF-α, IL-8 and RANKL25,26,27  
Clinically the activation of immune system and increased inflammation in RA correlate with 
joint erosions, bone mineral density and vertebral fractures.28 
In RA the inflammatory milieu increases OCs formation and activity both locally and 
systemically, several pro-inflammatory cytokines increased in RA are responsible for 
increased OCs formation and activity: IL-1 acts by increasing RANKL expression by bone 
marrow stromal cells and directly targets OCs precursors, promoting OCs differentiation 
in the presence of permissive levels of RANKL. The effect of TNF-α on 
osteoclastogenesis is upregulated by IL-1.6 In humans it has been demonstrated that anti-
TNF and anti-IL-1 monoclonal antibodies reduce bone resorption.29  
IL-6 is increased in RA and even though it is not essential for bone resorption it may 
contribute to the increased bone resorption in RA.30  
In RA and in other chronic inflammatory condition not only bone resorption, but also bone 
formation is affected. The increase in TNF-α during inflammation induces an increase in 
dickkopf-1 (DKK-1), that is a negative regulator of the Wnt pathway. Wnts are a family of 
secreted lipid-modified proteins that bind to a receptor complex comprising frizzled and 
the low-density lipoprotein receptor-related proteins 5 or 6 (LRP5 or LRP6). Activation of 
this receptor leads to induction of bone formation by OBs. DKK-1 and sclerostin (SOST) 
bind to and inactivate signalling from LRP5/LRP631 inhibiting bone formation. In RA it has 
been shown an increase in DKK-1 and SOST, this blunts OBs formation and activity and, 
together with the increase in bone resorption, is responsible for reduced bone mass32 and 
of the formation of articular bone erosions, in fact DKK-1 levels are associated with an 
increase in the number of articular erosions independently of age, baseline radiologic 
features, C-reactive protein, or disease activity.33  
Systemic bone loss has been correlated with inflammation also during aging and in other 
inflammatory diseases, the mechanisms are very similar to the ones demonstrated in 
RA.1  
Figure 1 summarizes the role of T cells in the regulation of osteoclastogenesis in RA. 
Estrogen loss, immune system and bone. 
Post-menopausal osteoporosis (PMO) is the most frequent metabolic skeletal disease, it 
is characterized by reduced bone mineral density and micro architectural deterioration of 
bone with increased fracture risk. In PMO the uncoupling between OB-mediated bone 
formation and OC-mediated bone resorption results in bone loss. Estrogen deficiency is 
the main driver of post-menopausal bone loss: during estrogen depletion OCs formation 
and activity are increased, this increase is partially mediated trough the effect of estrogen 
deficiency on immune system. 
Data on animals and humans demonstrated that both cellular and humoral immune 
responses are enhanced by estrogens.1 During estrogen deficiency immune response is 
altered and, in particular T cells, become more active and able to produce inflammatory 
and pro-osteoclastogenic cytokines as TNFα and RANKL. Despite of some inverse 
reports,34,35 the main body of literature firmly supports the essential role of activated T 
cells in regulating bone loss induced by estrogen deficiency,5,36,37,38 both in animal models 
and in humans. 
My lab and others demonstrated that in PMO osteoclastogenesis occurs only in the 
presence of T cells and that T cells of osteoporotic patients produce more RANKL and 
TNF-α, than controls,5 RANKL directly correlates with increases in bone resorption 
markers and inversely with serum estrogen levels.37 To confirm the effect of estrogen on 
cytokines production is noteworthy that hormone replacement therapy decreases the 
production of pro-osteoclastogenic cytokines in postmenopausal women.39  
One of the key mechanisms trough which estrogen deficiency induces proliferation and 
life-span of bone marrow T cells is the increase in antigen presentation by macrophages 
and dendritic cells,36 thanks to a greater expression of Class II TransActivator (CIITA), a 
transcriptional co-activator acting on MHCII promoter, with the final effect of up-regulation 
of MHCII on macrophages,23,36 these data have been generated in mice models, however 
also in humans a role for low-grade inflammation and MHC class II expression in bone 
loss has been suggested.40 T cells activation increases after OVX also thanks to the up-
regulation of CD40 ligand (CD40L) expression, the CD40/CD40L system is crucial for T-
cell activation and several functions of the immune system. It promotes macrophages 
activation and differentiation, antibody isotype switching, and the adequate organization 
of immunological memory in B cells. The increase in the number of activated CD40L-
expressing T cells after OVX promotes the expression of M-CSF and RANKL by stromal 
cells and down-regulates the production of OPG, this results in a significant increase in 
osteoclastogenesis.38 This mechanism has been demonstrated in mice and not confirmed 
in humans, nevertheless some papers confirm the role of estrogen in the regulation of 
immune function in humans in health or different diseases.41,42 In humans the effect of 
estrogens on immune function has been demonstrated in the ability to modulate T cells 
cytokines production,42,43 to answer to immune stimulation,44 whereas OVX increases T 
cells activation.5,43  
Estrogen deficiency increases the number of T cells also by increasing their thymic 
output, it has been demonstrated in humans that after ovariectomy (OVX) the size of the 
thymus increases, as well as in mice, and that T cells activation is increased after OVX.43  
In mice models Th17 cells have been implicated in OVX induced bone loss, these cells 
increased after OVX due to the up regulation of STAT3, ROR-ct and ROR-a and down 
regulation of Foxp3 which antagonizes Th17 cell differentiation.9 In humans a recent 
paper founds no effect of estradiol in the secretion of IL-17 by T cells in patients affected 
by multiple sclerosis,42 whereas another suggests that estradiol inhibited Th17 
differentiation through downregulation of Rorγt mRNA and protein expression.45 
Nevertheless in these studies the effect of estradiol was evaluated in vitro on cells from 
patients not in menopausal period and men, thus the results cannot be extended to 
women in menopause. We recently demonstrated both in mice and in humans a 
fundamental role for Th17 also in bone loss induced by primary hyperparathyroidism: we 
showed that IL-17 is upregulated by primary hyperparathyroidism in humans and by 
continuous PTH treatment in mice and that parathyroidectomy normalizes IL-17 
production.46  
Also B cells have recently been directly implicated in the regulation of bone resorption, 
these cells are able to produce OPG47 and, under certain conditions, could produce 
RANKL. B cell knock out mice are osteoporotic with enhanced osteoclastic bone 
resorption due to decreased OPG level.47 B cell OPG production is up-regulated by the 
activation of CD4038 thus T cell signaling to B cells, through CD40L and CD40 plays an 
important role in regulating basal OCs formation and in regulating bone homeostasis. 
During estrogen deficiency the up-regulation of CD40 enhances the cross talk between T 
and B cells. 
Activated B cells express RANKL, contributing to bone resorption,48 the number of 
RANKL-expressing B lymphocytes in the bone marrow increases after OVX,49, recently 
Onal and colleagues demonstrated that RANKL produced by B cells and not by T cells 
plays a role in OVX induced bone loss in mice50 (, this paper disagree with previous 
reports showing a foundamental role of RANKL produced by T cells in OVX induced bone 
loss (1, 5, 17, 36, 47).  In humans there are not convincing data on the role of B cells in 
post-menopausal osteoporosis, nevertheless changes in several B lymphocyte 
populations in patients affected by post-menopausal osteoporosis regardless to their 
estrogen status have been shown.51 The role of B cells in the control of bone turnover has 
been studied in other diseases that affect bone as RA48,52 and periodontal inflammation.53 
These studies suggest that B cells may be involved in the control of bone turnover also in 
humans mainly by the production of cytokines as OPG and RANKL. 
Figure 2 summarizes the role of immune system in the regulation of osteoclastogenesis 
in PMO. 
 
Gut microbiota, immune system and bone. 
The gut microbiota (GM) is the whole of the commensal bacteria living in our intestine, 
these are acquired at birth and can be considered a multicellular organ that 
communicates with and affects its host in numerous ways.  The GM composition tends to 
stabilization after the first 3-year after birth, in this period GM offers several antigens for 
the host's immune system and during this first 3 years the neonatal immune system 
reaches maturity under the influence of the GM and its relation with environmental factors 
as diet, infections, antibiotics and breastfeeding. The GM composition is extremely 
variable between individuals, its symbiotic relationship with the human host is useful in in 
food digestion and in fighting pathogens. 
Environmental factors as diet, antibiotic treatments and infections can change GM 
composition, recently it has been suggested that the altered gut colonization patterns, 
associated with decreasing microbial diversity, play a central role in human health and 
disease and are being increasingly implicated in the physiologic, immunologic, and 
metabolic deregulation seen in many several chronic non-communicable human diseases 
(NCDs).  Immune homeostasis disruption is the causal mechanism of NCDs as allergy, 
asthma, some autoimmune diseases, cardiovascular disease, metabolic disease, and 
neurodegenerative disorders, these disorders are characterized by a low grade of 
inflammation. Although inflammation and the pathways to disease are multifactorial, GM 
disbiosis may play a central role in the pathogenesis of these diseases.54  
Recent studies suggest that the GM may be involved also in the OVX induced bone loss 
trough the modulation of the immune system and, in particular, of T cells activation and 
pro-osteoclastogenic cytokines production. The most robust data have been produced in 
mice models, in particular, it has been shown that mice grown up in a bacteria free 
environment, i.d. mice with a sterile bowel called “germ-free” mice, have alteration of 
immune system and are protected by OVX induced bone loss. Germ free mice have an 
immature gut mucosal immune systems and a reduced number of T helper cells in the 
spleen, and in peripheral blood, this suggests that the GM is responsible for the correct 
development of systemic immunity.54  
Bone mass and density are increased in germ free mice due to decreased bone 
resorption, without alteration in bone formation.2 In these animals OCs formation is 
decreased thanks to a reduced number of T cells and of pro-inflammatory and pro-
osteoclastogenic cytokines as IL-6 and TNFα, these observations suggested that the 
effect of GM on bone turnover is mediated trough the modulation of immune system by 
GM.2 Fecal transplantation in germ-free animals with GM from mice raised in a 
conventional environment leads to a normalization of bone mass, T helper cells and OCs 
number. 
Animal data also suggested that the use of some strain of probioticts is able to prevent 
OVX induced bone loss55 and to increase bone formation by the up-regulation of genes 
involved in OBs formation and activity as Sparc and BMP-2.56 Also effects of prebiotics 
have been evaluated in animal models showing a positive effect on GM composition and 
subsequently on bone mass.57  
According to the data obtained in mice one may speculate that an unfavorable GM 
composition may increase inflammation and hence favors post-menopausal bone loss, 
however data obtained in humans are scarce.  There are no data linking a microbiome 
profile to the risk of post-menopausal bone loss, whereas data on possible effect of 
modifying GM through the use of pro and prebiotics are scarce.  
Another intriguing hypothesis on the effect of GM on bone is based on direct ability of GM 
to influence calcium absorption, a recent post-hoc analyses on the use of Lactobacillus 
reuteri showed an increased level of serum 25OH vitamin D in healthy subjects treated 
with this probiotic,58 as regards the use of prebiotics a recent study showed that 
supplementation with galactooligosaccharide in adolescent girls increased the presence of 
bifidobacteria in the GM, as previously shown in rat, and improved calcium absorption.59 A 
previous study demonstrated that a mixture of short- and long-chain inulin-type fructans, 
given as prebiotics during adolescence as oral supplements for a one-year period, 
increases bone mineralization and calcium absorption.60 A possible explanation of the 
effect of dietary or prebiotic fiber on bone metabolism is the effect of the fiber on calcium 
absorption; the microbiota ferment the fiber to short-chain fatty acids (SCFAs) reducing the 
gut pH, thus reducing the formation of calcium phosphates and increasing the calcium 
absorption favoring bone. In the studies on the effect of pre-biotics calcium absorption was 
investigated, whereas immune phenotype and inflammation were not. The effect of SCFAs 
may be more complex that the simple effect on gut pH and, indirectly, on calcium 
absorption, in fact some studies suggest that SCFAs increased calcium transport, whereas 
reducing gut pH with HCl did not; thus, SCFAs may be useful to improve the gut function 
and health. It has also been suggested that SCFAs influence calcium absorption trough 
signaling pathway modulation, infact butyrate modulates calcium absorption by non-gut 
cells61 .  
These seminal studies in in mice, and less clearly in humans, suggest that alteration of 
GM composition influences bone metabolism through different mechanisms. The most 
attracting hypothesis, as suggested by the findings from germ free mice, is that the GM 
influences bone turnover and mass by modulating the host's immune system, however 
other mechanisms, as influence on calcium absorption and on vitamin D synthesis, may 
also be involved. 
 
CONCLUSIONS. 
The interactions between immune system and bone are complex and play significant role 
in both health and disease, nevertheless not all the pathways discovered in animal 
models have been fully demonstrated in humans, and several challenging questions 
remains unsolved 
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Figure legend. 
Figure 1. The cartoon represents interaction between T cells and osteoclastogenesis in 
RA, continuous lines represent pathways demonstrated in humans, wherease dotted lines 
represent pathways not clearly demonstrated in humans.  
 
Figure 2. The cartoon represents interaction between estrogen deficiency, immune 
system and bone cells. 
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